The burgeoning landscape of therapy for obesity and type 2 glucose intolerance is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 https://finnianyohf301873.glifeblog.com/37589015/retatrutide-vs-tirzepatide-a-comparative-analysis